BioVector® GPER (GPR30) Stable Overexpressing Model Cell Line / GPER (GPR30) 膜雌激素受体高表达稳定转染细胞株

I Product General Information and Cellular Background

• Cell Line Variant Name: GPER-OE (or GPR30-OE Stable Cell Line models, standardly established on malignant or reporter backgrounds such as SKBr3, MCF-7, Hec-1A, or HeLa/SiHa).

• Receptor Identity and System Biology Background:

  GPER (G-Protein Coupled Estrogen Receptor), historically designated as GPR30, represents a non-classical, seven-transmembrane domain G-protein coupled receptor.It is structurally independent from the classical nuclear/genomic steroid receptors, Estrogen Receptor Alpha ($ER\alpha$) and Estrogen Receptor Beta ($ER\beta$).

  While classical ERs act predominantly as ligand-activated transcription factors that regulate gene transcription via Estrogen Response Elements (ERE) over hours or days, GPER directs rapid, "non-genomic" membrane signaling events.Upon binding to 17$\beta$-estradiol ($E_2$), GPER triggers intracellular responses within seconds or minutes.

  Remarkably, GPER exhibits distinct ligand-binding mechanics compared to classical ERs; selective estrogen receptor modulators (SERMs) like Tamoxifen and full estrogen receptor antagonists like Fulvestrant (ICI 182,780), which switch off $ER\alpha$, act as functional chemical agonists when binding to GPER, driving paradoxically pro-proliferative or anti-apoptotic downstream survival cascades in specific cancer microenvironments.

• Engineering Architecture and Selection Footprint:

  To overcome the low endogenous expression and signaling noise seen in mixed-receptor backgrounds, BioVector® established the GPER-OE line using lentiviral or transposon-mediated integration. The human GPER1 open reading frame (ORF, ~1125 bp) is driven by a strong, constitutive mammalian promoter (pCMV or pEF1$\alpha$). The integration cassette includes a downstream internal ribosome entry site (IRES) or 2A peptide linked to a Puromycin ($Puro^R$) or Blasticidin ($Bsd^R$) antibiotic resistance gene, ensuring a stable, highly homogenous overexpressing cell population.

II Intracellular Signaling Cascades and Strategic Research Value

The GPER-OE model cell line serves as a targeted tool to isolate and map non-genomic estrogen pathways without interference from classical nuclear receptor signaling:

                  [ 17β-Estradiol / Tamoxifen / G-1 Agonist ]                                      │                                      ▼                        ┌───────────────────────────┐                        │    GPER (GPR30) Receptor  │  (7-Transmembrane GPCR)                        └─────────────┬─────────────┘                                      │                    ┌─────────────────┴─────────────────┐                    ▼                                   ▼          [ Gs/Gi Protein Activation ]        [ Gβγ Subunit Release ]                    │                                   │                    ▼                                   ▼         [ Adenylyl Cyclase (AC) ]            [ MMP Cleavage / Activation ]                    │                                   │                    ▼                                   ▼           [ cAMP Generation ]                     [ sEGF Release ]                    │                                   │                    ▼                                   ▼        [ Protein Kinase A (PKA) ]            [ EGFR Transactivation ]                    │                                   │                    ▼                                   ▼        [ Intracellular Ca²⁺ Release ]      [ PI3K/Akt & MAPK/ERK1/2 ]                    │                                   │                    └─────────────────┬─────────────────┘                                      ▼                      [ Rapid Cell Proliferation, ]                      [ Survival & Drug Resistance]

1. EGFR Transactivation and Kinase Cascade Activation:

   Upon ligand binding, GPER recruits heterotrimeric G-proteins, causing the $G\beta\gamma$ subunits to activate matrix metalloproteinases (MMPs).These enzymes cleave heparin-binding EGF-like growth factor (HB-EGF), releasing soluble EGF to transactivate the Epidermal Growth Factor Receptor (EGFR). This cross-talk drives rapid phosphorylation of the MAPK/ERK1/2 and PI3K/Akt survival pathways, stimulating cell cycle progression and cell migration.

2. Adenylate Cyclase and Calcium Mobilization Loops:

   GPER activation simultaneously stimulates adenylyl cyclase (AC), generating cyclic AMP (cAMP) and activating Protein Kinase A (PKA).This pathway triggers the mobilization of intracellular calcium ($Ca^{2+}$) stores from the endoplasmic reticulum, altering cellular contractility, metabolic flux, and immediate-early gene expression (e.g., c-Fos).

3. Endocrine Disruption and Xenoestrogen Screening:

   The GPER-OE line serves as a high-sensitivity biosensor for environmental toxicology. It maps how low, environmentally relevant doses of endocrine-disrupting chemicals (EDCs) like Bisphenol A (BPA), nonylphenol, and certain pesticides bind to membrane receptors, bypassing classical ER pathways to trigger oncogenic signaling.

4. Dissecting Mechanisms of Tamoxifen Resistance:

   In $ER\alpha$-positive breast cancers, long-term Tamoxifen therapy often leads to drug resistance. Using GPER-OE lines, researchers can study how Tamoxifen shifts from an antagonist in the nucleus to an agonist at the plasma membrane, driving the expression of multidrug resistance proteins like ABCG2.

III Laboratory Thawing, Cultivation, Selection Maintenance, and Assay Assays

1. Complete Growth Medium Formulations and Selection Limits

• Basal Medium Base (Critical Selection Phenotype):

  • For Routine Expansion: Premium High-Glucose DMEM or RPMI-1640 depending on the parental cell line background.

  • For Estrogen-Sensitive Signaling Assays (Mandatory Quality Control): Researchers must substitute standard basal media with Phenol Red-Free DMEM or Phenol Red-Free RPMI-1640. Phenol red acts as a weak classical estrogen agonist and can cause significant baseline signaling noise.

• Serum Supplementation Guidelines:

  • For Routine Expansion: Supplement with 10% premium Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.

  • For Functional Assays: Standard FBS contains significant levels of endogenous steroids. For ligand-binding, calcium flux, or western blot experiments, the medium must be supplemented with 5% – 10% Charcoal-Stripped FBS (CS-FBS) for at least 48 hours prior to assay initiation to deplete background hormones.

• Antibiotic Selection Maintenance Pressure: To prevent silencing of the expression cassette, maintain routine cultures under selection pressure using $1.0 - 2.5\ \mu\text{g/mL}$ Puromycin or $5 - 10\ \mu\text{g/mL}$ Blasticidin (verify batch specifications). Note: Remove selection antibiotics during active assay windows to avoid confounding cytotoxicity measurements.

2. Cryovial Thawing and Monolayer Recovery Protocol

1. Pre-warm 5 mL of complete expansion medium (containing standard 10% FBS, without selection antibiotics) in a sterile T25 culture flask to 37 °C.

2. Retrieve the GPER-OE cryovial from liquid nitrogen storage and submerge it instantly into a 37 °C water bath. Agitate rapidly to melt the internal volume within 60 seconds.

3. Spray the cryovial with 75% ethanol and transfer it to the biosafety cabinet.

4. Transfer the cell suspension slowly into a 15 mL conical tube containing 4 mL of pre-warmed complete growth medium.

5. Centrifuge at 1000 rpm (~200 g) for 5 minutes to pellet the cells.

6. Aspirate the DMSO-containing supernatant, resuspend the cell pellet gently in 2 mL of fresh expansion medium, and seed into the prepared T25 flask.

7. Change the medium completely after 24 hours to remove residual unattached cells. Once the cell monolayer enters active log phase expansion, re-introduce the appropriate selection antibiotic.

3. Routine Adherent Passaging Protocols

• Confluency Assessment Control: Initialize passaging when the adherent monolayer reaches 80% – 85% confluency. Do not allow the culture to become over-confluent ($\gt 90\%$), as contact inhibition and local metabolic accumulation can downregulate the CMV/EF1$\alpha$ promoter vectors, leading to lower receptor expression levels over time.

• Passaging Execution Steps:

  1. Aspirate the spent culture medium and rinse the cell layer once with sterile, calcium/magnesium-free PBS.

  2. Add an appropriate volume of 0.25% Trypsin-EDTA solution (e.g., 1 mL for a T25 flask) to cover the monolayer, and incubate at 37 °C.

  3. Monitor dissociation under an inverted microscope. Detachment typically occurs within 1 – 3 minutes. As soon as the cells round up and loosen upon gentle tapping, add 2 volumes of serum-fortified complete medium to deactivate the trypsin.

  4. Pipette gently to dissociate cell aggregates into a single-cell suspension.

  5. Centrifuge at 1000 rpm for 5 minutes, discard the supernatant, and resuspend the pellet in fresh complete selection medium.

  6. Split the culture into new culture vessels at standard ratios of 1:3 to 1:5.

4. Quality Control Safeguards and Functional Validation Blueprints

1. Receptor Overexpression Audits: Periodically verify GPER expression levels every 10 passages using RT-qPCR (to measure mRNA levels) and Western Blotting or Flow Cytometry (FACS) (to confirm surface protein abundance). Use anti-GPER specific antibodies to monitor expression stability and guard against clonal drift.

2. Pharmacological Baseline Testing: Before initiating large-scale screens, validate receptor functionality using selective small-molecule tools:

   • G-1 (Selective GPER Agonist): Should rapidly induce ERK1/2 and Akt phosphorylation within 5–15 minutes in Phenol Red-free/CS-FBS conditioned media.

   • G-15 or G-30 (Selective GPER Antagonists): Pre-incubating cells with these antagonists should block G-1 or Tamoxifen-mediated kinase activation.

5. Long-Term Cryopreservation Parameters

• Cryoprotectant Freezing Formulation: 55% basal growth medium + 35% premium Fetal Bovine Serum (FBS) + 10% analytical-grade Dimethyl Sulfoxide (DMSO), or a certified high-performance commercial cryopreservation matrix.

• Controlled-Rate Freezing Workflow:

  1. Harvest cells during active mid-log phase growth (approximately 80% confluent), ensuring high initial viability ($\gt 95\%$). Centrifuge to collect the cell pellet.

  2. Resuspend the pellet in pre-chilled cryoprotectant matrix to achieve a final density of $1.5 \times 10^6$ to $3.0 \times 10^6$ viable cells per milliliter.

  3. Transfer into sterile cryovials, secure the caps, and place immediately into a controlled-rate freezing container (e.g., Mr. Frosty).

  4. Store the container in a -80 °C ultra-low freezer overnight to achieve a steady cooling rate of -1 °C/minute.

  5. Within 24 hours, transfer the cryovials into liquid nitrogen storage tanks (-196 °C) for long-term preservation. Avoid extended storage at -80 °C to prevent promoter silencing and preserve cell viability.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net